The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Abstract
PURPOSE: To evaluate our long-term experience with patients treated uniformly with radical cystectomy and pelvic lymph node dissection for invasive bladder cancer and to describe the association of the primary bladder tumor stage and regional lymph node status with clinical outcomes. PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 and December 1997, with or without adjuvant radiation or chemotherapy, were evaluated. The clinical course, pathologic characteristics, and long-term clinical outcomes were evaluated in this group of patients. RESULTS: A total of 1,054 patients (843 men [80%] and 211 women) with a median age of 66 years (range, 22 to 93 years) were uniformly treated. Median follow-up was 10.2 years (range, 0 to 28 years). There were 27 (2.5%) perioperative deaths, with a total of 292 (28%) early complications. Overall recurrence-free survival at 5 and 10 years for the entire cohort was 68% and 66%, respectively. The 5- and 10-year recurrence-free survival for patients with organ-confined, lymph node–negative tumors was 92% and 86% for P0 disease, 91% and 89% for Pis, 79% and 74% for Pa, and 83% and 78% for P1 tumors, respectively. Patients with muscle invasive (P2 and P3a), lymph node–negative tumors had 89% and 87% and 78% and 76% 5- and 10-year recurrence-free survival, respectively. Patients with nonorgan-confined (P3b, P4), lymph node–negative tumors demonstrated a significantly higher probability of recurrence compared with those with organ-confined bladder cancers (P < .001). The 5- and 10-year recurrence-free survival for P3b tumors was 62% and 61%, and for P4 tumors was 50% and 45% , respectively. A total of 246 patients (24%) had lymph node tumor involvement. The 5- and 10-year recurrence-free survival for these patients was 35%, and 34%, respectively, which was significantly lower than for patients without lymph node involvement (P < .001). Patients could also be stratified by the number of lymph nodes involved and by the extent of the primary bladder tumor (p stage). Patients with fewer than five positive lymph nodes, and whose p stage was organ-confined had significantly improved survival rates. Bladder cancer recurred in 311 patients (30%) . The median time to recurrence among those patients in whom the cancer recurred was 12 months (range, 0.04 to 11.1 years). In 234 patients (22%) there was a distant recurrence, and in 77 patients (7%) there was a local (pelvic) recurrence. CONCLUSION: These data from a large group of patients support the aggressive surgical management of invasive bladder cancer. Excellent long-term survival can be achieved with a low incidence of pelvic recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Miller, R. G. (1981) · Cited by 3,336
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Chi-Square Tests with One Degree of Freedom; Extensions of the Mantel-Haenszel Procedure
Mantel, N. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500879 · Cited by 2,897
International Union against Cancer
(1959) · Journal of the Faculty of Radiologists · doi:10.1016/s0368-2242(59)80060-9 · Cited by 1,220
Skinner, D. G., Daniels, J. R., Russell, C. A., Lieskovsky, G., Boyd, S. D., Nichols, P., Kern, W., Sakamoto, J., Krailo, M., & Groshen, S. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)38368-4 · Cited by 524
Self-citationGaynor, J. J., Feuer, E. J., Tan, C. C., Wu, D. H., Little, C. R., Straus, D. J., Clarkson, B. D., & Brennan, M. F. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10476289 · Cited by 483
Radical Cystectomy for Carcinoma of the Bladder: Critical Evaluation of the Results in 1,026 Cases
Ghoneim, M. A., El-Mekresh, M. M., El-Baz, M. A., Elattar, I. A., & Ashamallah, A. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64487-2 · Cited by 447
Cited by
Lenis, A. T., Lec, P. M., Chamie, K., & MSHS, M. (2020) · JAMA · doi:10.1001/jama.2020.17598 · Cited by 2,051
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
Alfred Witjes, J., Lebret, T., Compérat, E. M., Cowan, N. C., De Santis, M., Bruins, H. M., Hernández, V., Espinós, E. L., Dunn, J., Rouanne, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.020 · Cited by 1,476
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034442 · Cited by 1,065
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,014
Kaufman, D. S., Shipley, W. U., & Feldman, A. S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60491-8 · Cited by 988
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106106 · Cited by 962
Hall, M. C., Chang, S. S., Dalbagni, G., Pruthi, R. S., Seigne, J. D., Skinner, E. C., Wolf, J. S., & Schellhammer, P. F. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.09.003 · Cited by 830
Self-citationSanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 814
Parekh, D. J., Reis, I. M., Castle, E. P., Gonzalgo, M. L., Woods, M. E., Svatek, R. S., Weizer, A. Z., Konety, B. R., Tollefson, M., Krupski, T. L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30996-6 · Cited by 790
Self-citationNecchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741
Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy
Madersbacher, S., Hochreiter, W., Burkhard, F., Thalmann, G. N., Danuser, H., Markwalder, R., & Studer, U. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.101 · Cited by 763
Shariat, S. F., Karakiewicz, P. I., Palapattu, G. S., Lotan, Y., Rogers, C. G., Amiel, G. E., Vazina, A., Gupta, A., Bastian, P. J., Sagalowsky, A. I., et al. (2006) · Journal of Urology · doi:10.1016/j.juro.2006.08.004 · Cited by 709
Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., & Witjes, J. A. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.023 · Cited by 677
Panebianco, V., Narumi, Y., Altun, E., Bochner, B. H., Efstathiou, J. A., Hafeez, S., Huddart, R., Kennish, S., Lerner, S., Montironi, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.04.029 · Cited by 658
Self-citationctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., et al. (2021) · Nature · doi:10.1038/s41586-021-03642-9 · Cited by 646
The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer
Stenzl, A., Cowan, N. C., De Santis, M., Jakse, G., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., & Witjes, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.01.002 · Cited by 639
Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P., Kaufman, D. S., Heney, N. M., & Zietman, A. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5548 · Cited by 465
Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer
(2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3884 · Cited by 460
Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438
Efstathiou, J. A., Spiegel, D. Y., Shipley, W. U., Heney, N. M., Kaufman, D. S., Niemierko, A., Coen, J. J., Skowronski, R. Y., Paly, J. J., McGovern, F. J., et al. (2012) · European Urology · doi:10.1016/j.eururo.2011.11.010 · Cited by 435
Bellmunt, J., Hussain, M., Gschwend, J. E., Albers, P., Oudard, S., Castellano, D., Daneshmand, S., Nishiyama, H., Majchrowicz, M., Degaonkar, V., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00004-8 · Cited by 429
Gakis, G., Efstathiou, J., Lerner, S. P., Cookson, M. S., Keegan, K. A., Guru, K. A., Shipley, W. U., Heidenreich, A., Schoenberg, M. P., Sagaloswky, A. I., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.009 · Cited by 422
Hautmann, R. E., de Petriconi, R. C., Pfeiffer, C., & Volkmer, B. G. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.028 · Cited by 417
van Dijk, N., Gil-Jimenez, A., Silina, K., Hendricksen, K., Smit, L. A., de Feijter, J. M., van Montfoort, M. L., van Rooijen, C., Peters, D., Broeks, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1085-z · Cited by 404
Sternberg, C. N., Skoneczna, I., Kerst, J. M., Albers, P., Fossa, S. D., Agerbaek, M., Dumez, H., de Santis, M., Théodore, C., Leahy, M. G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71160-x · Cited by 389
The effect of age and gender on bladder cancer: a critical review of the literature
Shariat, S. F., Sfakianos, J. P., Droller, M. J., Karakiewicz, P. I., Meryn, S., & Bochner, B. H. (2010) · BJU International · doi:10.1111/j.1464-410x.2009.09076.x · Cited by 371
Self-citationUrothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins
Green, D. A., Rink, M., Xylinas, E., Matin, S. F., Stenzl, A., Roupret, M., Karakiewicz, P. I., Scherr, D. S., & Shariat, S. F. (2013) · Journal of Urology · doi:10.1016/j.juro.2012.05.079 · Cited by 362
Lee, R. K., Abol‐Enein, H., Artibani, W., Bochner, B., Dalbagni, G., Daneshmand, S., Fradet, Y., Hautmann, R. E., Lee, C. T., Lerner, S. P., et al. (2014) · BJU International · doi:10.1111/bju.12121 · Cited by 360
Self-citationPositron emission tomography for prostate, bladder, and renal cancer
Schöder, H., & Larson, S. M. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2004.06.004 · Cited by 337
Bladder Cancer in 2010: How Far have We Come?
Jacobs, B. L., Lee, C. T., & Montie, J. E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20077 · Cited by 336
Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma
Hoskin, P. J., Rojas, A. M., Bentzen, S. M., & Saunders, M. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4950 · Cited by 332
Real-world data: towards achieving the achievable in cancer care
Booth, C. M., Karim, S., & Mackillop, W. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0167-7 · Cited by 327
P53 as a prognostic marker for bladder cancer: a meta-analysis and review
Malats, N., Bustos, A., Nascimento, C. M., Fernandez, F., Rivas, M., Puente, D., Kogevinas, M., & Real, F. X. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70315-6 · Cited by 317
Mowatt, G., Zhu, S., Kilonzo, M., Boachie, C., Fraser, C., Griffiths, T., N'Dow, J., Nabi, G., Cook, J., & Vale, L. (2010) · Health Technology Assessment · doi:10.3310/hta14040 · Cited by 313
HERR, H., LEE, C., CHANG, S., LERNER, S., & for the Bladder Cancer Collaborative Group (2004) · Journal of Urology · doi:10.1097/01.ju.0000120289.78049.0e · Cited by 291
Boorjian, S. A., Sheinin, Y., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., Leibovich, B. C., Kwon, E. D., & Frank, I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0731 · Cited by 270
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature
Kluth, L. A., Black, P. C., Bochner, B. H., Catto, J., Lerner, S. P., Stenzl, A., Sylvester, R., Vickers, A. J., Xylinas, E., & Shariat, S. F. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.032 · Cited by 265
Self-citationNomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy
Shariat, S. F., Karakiewicz, P. I., Palapattu, G. S., Amiel, G. E., Lotan, Y., Rogers, C. G., Vazina, A., Bastian, P. J., Gupta, A., Sagalowsky, A. I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0372 · Cited by 263
SÁNCHEZ-ORTIZ, R. F., HUANG, W. C., MICK, R., VAN ARSDALEN, K. N., WEIN, A. J., & MALKOWICZ, S. B. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)64047-5 · Cited by 261
Dash, A., Pettus, J. A., Herr, H. W., Bochner, B. H., Dalbagni, G., Donat, S. M., Russo, P., Boyle, M. G., Milowsky, M. I., & Bajorin, D. F. (2008) · Cancer · doi:10.1002/cncr.23848 · Cited by 258
Self-citationComplications after radical cystectomy: Analysis of population-based data
Konety, B. R., Allareddy, V., & Herr, H. (2006) · Urology · doi:10.1016/j.urology.2006.01.051 · Cited by 256
Stimson, C. J., Chang, S. S., Barocas, D. A., Humphrey, J. E., Patel, S. G., Clark, P. E., Smith, J. A., & Cookson, M. S. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.06.007 · Cited by 256
Al-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16318 · Cited by 163
CD24 Is an Effector of HIF-1–Driven Primary Tumor Growth and Metastasis
Thomas, S., Harding, M. A., Smith, S. C., Overdevest, J. B., Nitz, M. D., Frierson, H. F., Tomlins, S. A., Kristiansen, G., & Theodorescu, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3666 · Cited by 128
“contributes most strongly to overall survival (40).”
Longer Wait Times Increase Overall Mortality in Patients With Bladder Cancer
Kulkarni, G. S., Urbach, D. R., Austin, P. C., Fleshner, N. E., & Laupacis, A. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.06.041 · Cited by 123
Thomas, S., Overdevest, J. B., Nitz, M. D., Williams, P. D., Owens, C. R., Sanchez-Carbayo, M., Frierson, H. F., Schwartz, M. A., & Theodorescu, D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0730 · Cited by 92
Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88
Self-citationAfshar, M., Goodfellow, H., Jackson‐Spence, F., Evison, F., Parkin, J., Bryan, R. T., Parsons, H., James, N. D., & Patel, P. (2018) · BJU International · doi:10.1111/bju.13929 · Cited by 67
Metadata
- Authors
- Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A.-C., Boyd, S., Skinner, E., Bochner, B., Thangathurai, D., Mikhail, M., Raghavan, D., & Skinner, D. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-02-01
- Volume
- 19
- Issue
- 3
- Pages
- 666-675
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113156769
- Cited by
- 3,530
- References
- 13
- FWCI
- 57.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.